The ability of lovastatin in depleting CAV1 protein in a transient manner is also a potential pharmacological strategy in molecular imaging with antibody fragments and engineered variants because these biomolecules exhibit faster accumulation in the tumor tissue than do fully intact antibodies. Here, CAV1 is linked to neoplasm.